In this podcast Anne Wilson, CEO Emerge Australia, is in a fascinating conversation with Dr Alain Moreau, hot on the heels of his enlightening November keynote address at The National Centre for Neuroimmunology and Emerging Diseases, ME/CFS and long COVID International Conference in northern New South Wales.
Dr Moreau is a Full Professor in the Faculty of Dentistry (Stomatology Department), cross-appointed to the Biochemistry and Molecular Medicine Department in the Faculty of Medicine at Université de Montréal. He served as Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital (2013-2016). He is currently Director of The Network for Canadian Oral Health Research (NCOHR), and he serves on the Advisory Board of the Institute of Musculoskeletal Health and Arthritis of The Canadian Institutes of Health Research (CIHR).
More recently, Professor Moreau was appointed Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis (ICanCME) Research Network, another national research network funded by CIHR. He is an internationally recognized expert on the molecular genetics of paediatric scoliosis. His discoveries led to multiple peer-reviewed papers, international conferences as a guest speaker, several awards as well as 60 patents covering innovative diagnostic tests and therapeutic molecules.
Professor Moreau is the co-founder and Chief Scientific Officer of Inception Therapeutic Inc., a start-up based in Montreal developing diagnostic tests for primary osteoarthritis and new disease-modifying osteoarthritis drugs. Dr. Moreau’s primary research interests also target other complex adult diseases such as osteoporosis and ME/CFS.
